This trial uses two existing cancer drugs to see if jointly they increase the survival rate.
Given the ugly side effects, and the liklihood that a marginal but improved outcome is found - I would call this a complimentary treatment to cvac, and possibly subordinate.
The main competition I see (and again it will probably be complimentary) is NV-128 by Novogen but hasn't begun human trials yet.
One of the main pluses to cvac is doesn't have the nasty side effects of chemo and the drugs in the trial above.
- Forums
- ASX - By Stock
- IMM
- competition
competition, page-2
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
28.5¢ |
Change
-0.005(1.72%) |
Mkt cap ! $413.9M |
Open | High | Low | Value | Volume |
29.0¢ | 29.5¢ | 28.0¢ | $1.441M | 5.001M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 102393 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.0¢ | 14707 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 102393 | 0.285 |
13 | 285561 | 0.280 |
13 | 499761 | 0.275 |
19 | 419400 | 0.270 |
6 | 127774 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.290 | 14707 | 1 |
0.295 | 116416 | 4 |
0.300 | 121711 | 4 |
0.305 | 10000 | 1 |
0.310 | 249310 | 6 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO & MD
Anthony Noble
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online